Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

LAMA

Gilead Sciences

Sovaldi pushes Gilead to the top of US pharma list

Blockbuster hep c pill sees the firm go from fourteenth to first in just one year

- PMLiVE

AstraZeneca and EHR firm to use drug alert system

Firm will team up with Practice Fusion to help keep patients on the right treatment pathway

- PMLiVE

ReNeuron aiming to take second stem cell therapy into clinic

Will test its human retinal progenitor cell for genetic eye disease RP

- PMLiVE

FDA reviewer backs approval of TMC’s cangrelor

Claims it offers a small benefit over Sanofi’s Plavix

- PMLiVE

AZ’s Onglyza may increase mortality, says FDA

Kombiglyze also under scrutiny

- PMLiVE

US cancer drug prices ‘not rational’

New research from the medical journal JAMA adds to growing pressure over pricing

- PMLiVE

UK to pay for GSK’s MenB vaccine after year’s delay

British firm says the deal offers ‘fair value’ to the NHS

Eli Lilly HQ

Pfizer and Lilly restart tanezumab pain trials

FDAlifts clinical block on late-stage studies of the novel painkiller

- PMLiVE

R&D productivity takes off

Approvals of NMEs reach heights last seen in the mid-1990s

- PMLiVE

AstraZeneca scores in final lung disease drug trials

The firm hopes it LAMA/LABA drug can take a big chunk from the $14bn COPD market

- PMLiVE

US approval for Astellas’ new antifungal drug Cresemba

Japanese firm co-markets the azole antifungal agent with Basilea

- PMLiVE

FDA approves first biosimilar

Novartis’ Sandoz unit gains new licence for Neupogen copycat

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links